DNA Damage Is a Potential Marker for TP53 Mutation in Colorectal Carcinogenesis

被引:0
作者
Scalise J.R. [1 ]
Poças R.C.G. [1 ]
Caneloi T.P. [2 ]
Lopes C.O. [2 ]
Kanno D.T. [2 ]
Marques M.G. [2 ]
Valdivia J.C.M. [2 ]
Maximo F.R. [2 ]
Pereira J.A. [3 ]
Ribeiro M.L. [1 ]
Priolli D.G. [1 ,4 ]
机构
[1] Postgraduate Programme Strictu Senso in Health Science, Sao Francisco University Medical School, Sao Paulo
[2] Scientific Initiation Student, Scientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo
[3] Department of Pathology, Sao Francisco University Medical School, Sao Paulo
[4] Rua São Vicente 614. Jardim Paulista, Atibaia, CEP: 12947-390, SP
基金
巴西圣保罗研究基金会;
关键词
Adenocarcinoma; Adenoma; DNA damage; Immunohistochemistry; Tumor suppressor protein p53;
D O I
10.1007/s12029-016-9846-0
中图分类号
学科分类号
摘要
Purpose: The ability to measure oxidative DNA damage in a tissue allows establishment of the relationship between DNA damage and mutations in normal and neoplastic cells. It is well known that TP53 is a key inhibitor of tumor development and preserves the genome integrity in each cell. The aim of the present study was to investigate the relationship between DNA damage and TP53 mutation in colorectal adenoma and adenocarcinoma, and the value of DNA damage as potential marker of TP53 mutation in non-tumor tissues adjacent to colon malignant lesions. Methods: Tissue samples were obtained by colonoscopy from patients with adenoma and/or adenocarcinoma and from healthy volunteers. Diagnosis was defined by histopathology. Immunohistochemistry with computer-assisted image analysis was performed to quantify TP53 mutation. Oxidative DNA damage was determined by comet assay. Statistical analyses were performed with 5 % of significance level. Results: The TP53 level was higher in non-tumor tissues from tumor patients than in normal tissues from healthy volunteers (p = 0.01). Likewise, higher TP53 levels were observed in tumor tissues compared with the non-tumor tissues (p = 0.00). Oxidative DNA damage levels were higher in tumor tissues than in non-tumor tissues (p = 0.00). The amount of TP53 (p = 0.00) and oxidative DNA damage (p = 0.00) in normal and tumor tissue was related. The relationship between oxidative DNA damage and TP53 mutation was demonstrated in all samples (p = 0.00). Conclusion: Oxidative DNA damage is an intervening variable for TP53 mutation in colorectal adenoma-carcinoma. Our data suggests that oxidative DNA damage is a potential marker of TP53 mutation in colorectal carcinogenesis. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:409 / 416
页数:7
相关论文
共 50 条
  • [31] Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice
    Duan, Wenrui
    Gao, Li
    Kalvala, Arjun
    Aguila, Brittany
    Brooks, Christopher
    Mo, Xiaokui
    Ding, Haiming
    Shilo, Konstantin
    Otterson, Gregory A.
    Villalona-Calero, Miguel A.
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (09) : 2418 - 2426
  • [32] Extremely High Tp53 Mutation Load in Esophageal Squamous Cell Carcinoma in Golestan Province, Iran
    Abedi-Ardekani, Behnoush
    Kamangar, Farin
    Sotoudeh, Masoud
    Villar, Stephanie
    Islami, Farhad
    Aghcheli, Karim
    Nasrollahzadeh, Dariush
    Taghavi, Noushin
    Dawsey, Sanford M.
    Abnet, Christian C.
    Hewitt, Stephen M.
    Fahimi, Saman
    Saidi, Farrokh
    Brennan, Paul
    Boffetta, Paolo
    Malekzadeh, Reza
    Hainaut, Pierre
    PLOS ONE, 2011, 6 (12):
  • [33] Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis
    Toyoda, Tomoaki
    Miura, Nami
    Kato, Shingo
    Masuda, Takeshi
    Ohashi, Ryuji
    Matsushita, Akira
    Matsuda, Fumio
    Ohtsuki, Sumio
    Katakura, Akira
    Honda, Kazufumi
    CANCER SCIENCE, 2024, 115 (11) : 3622 - 3635
  • [34] Putative colon cancer risk factors damage global DNA and TP53 in primary human colon cells isolated from surgical samples
    Schaeferhenrich, A
    Sendt, W
    Scheele, J
    Kuechler, A
    Liehr, T
    Claussen, U
    Rapp, A
    Greulich, KO
    Pool-Zobel, BL
    FOOD AND CHEMICAL TOXICOLOGY, 2003, 41 (05) : 655 - 664
  • [35] Alterations in PTEN, MDM2, TP53 and AR protein and gene expression are associated with canine prostate carcinogenesis
    Rivera-Calderon, Luis Gabriel
    Fonseca-Alves, Carlos Eduardo
    Kobayashi, Priscila Emiko
    Carvalho, Marcio
    Drigo, Sandra Aparecida
    Vasconcelos, Rosemeri de Oliveira
    Laufer-Amorim, Renee
    RESEARCH IN VETERINARY SCIENCE, 2016, 106 : 56 - 61
  • [36] Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains An Uncommon But Potential Diagnostic Pitfall With Clinical Implications
    Rabban, Joseph T.
    Garg, Karuna
    Ladwig, Nicholas R.
    Zaloudek, Charles J.
    Devine, W. Patrick
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (11) : 1441 - 1451
  • [37] Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing
    Lee, Hyunwoo
    Cho, Yoon ah
    Kim, Deok geun
    Son, Jae young
    Cho, Eun yoon
    ANTICANCER RESEARCH, 2024, 44 (09) : 3983 - 3994
  • [38] Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ
    Munn, KE
    Walker, RA
    Menasce, L
    Varley, JM
    BRITISH JOURNAL OF CANCER, 1996, 74 (10) : 1578 - 1585
  • [39] A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma
    A J Davies
    A M Lee
    C Taylor
    A J Clear
    L K Goff
    S Iqbal
    D Cuthbert-Heavens
    M Calaminici
    A J Norton
    T A Lister
    J Fitzgibbon
    Leukemia, 2005, 19 : 1459 - 1465
  • [40] The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
    Biatta, Chiara M.
    Paudice, Michele
    Greppi, Marco
    Parrella, Veronica
    Parodi, Alessia
    De Luca, Giuseppa
    Cerruti, Gianna Maria
    Mammoliti, Serafina
    Caroti, Cinzia
    Menichini, Paola
    Fronza, Gilberto
    Pesce, Silvia
    Marcenaro, Emanuela
    Vellone, Valerio G.
    FRONTIERS IN IMMUNOLOGY, 2023, 14